Clinical Trial: NCT05594095
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Status:
RECRUITINGPhase:
Phase 2| Lead Sponsor: | Fudan University |
| Information Provided By: | Fudan University |
| Last Update Posted: | 2024-10-04 |
Study Overview
Brief Summary
The purpose of this study is to establish a prospective, multi-center platform research based on clinical subtypes to explore precision therapy in patients hormone-receptor-positive HER2-negative advanced breast cancer who had previously used CDK4/6 inhibitors.
Official Title
Precision Platform Study of HR+/ HER2-advanced Breast Cancer Based on SNF Typing (A Prospective, Open-label, Multi-center, Phase II Platform Study)
Conditions
Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer, Advanced Breast Cancer
Intervention / Treatment
- Drug: PIK3CA inhibitor
- Drug: AKT inhibitor
- Drug: Carrelizumab
- Drug: Famitinib
- Drug: Fluzoparib
- Drug: Dalpiciclib
- Drug: SHR-A1811
- Drug: Everolimus
- Drug: Aromatase Inhibitors or Fulvestrant
- Drug: Goserelin
- Drug: TPC
- Drug: Sorafenib
- Drug: Apatinib
- Drug: SHR-A1921
- Drug: SHR-A2102
- Drug: SHR-A2009
- Drug: SHR-1167
- Drug: SHR-6209
- Drug: bevacizumab
Other Study ID Numbers
- BCTOP-L-M05
Start Date (Actual)
2022-12-30
Primary Completion Date (Estimated)
2025-12-01
Study Completion Date (Estimated)
2026-12-01
Enrollment (Estimated)
620
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Fudan University |
| Information Provided By: | Fudan University |
| Last Update Posted: | 2024-10-04 |
Study Overview
Brief Summary
The purpose of this study is to establish a prospective, multi-center platform research based on clinical subtypes to explore precision therapy in patients hormone-receptor-positive HER2-negative advanced breast cancer who had previously used CDK4/6 inhibitors.
Official Title
Precision Platform Study of HR+/ HER2-advanced Breast Cancer Based on SNF Typing (A Prospective, Open-label, Multi-center, Phase II Platform Study)
Conditions
Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer, Advanced Breast Cancer
Intervention / Treatment
- Drug: PIK3CA inhibitor
- Drug: AKT inhibitor
- Drug: Carrelizumab
- Drug: Famitinib
- Drug: Fluzoparib
- Drug: Dalpiciclib
- Drug: SHR-A1811
- Drug: Everolimus
- Drug: Aromatase Inhibitors or Fulvestrant
- Drug: Goserelin
- Drug: TPC
- Drug: Sorafenib
- Drug: Apatinib
- Drug: SHR-A1921
- Drug: SHR-A2102
- Drug: SHR-A2009
- Drug: SHR-1167
- Drug: SHR-6209
- Drug: bevacizumab
Other Study ID Numbers
- BCTOP-L-M05
Start Date (Actual)
2022-12-30
Primary Completion Date (Estimated)
2025-12-01
Study Completion Date (Estimated)
2026-12-01
Enrollment (Estimated)
620
Study Type
Interventional
Phase
Phase 2